Oppenheimer Lowers Alnylam Price Target to $320 From $350, Keeps Outperform
Oppenheimer lowered its price target on Alnylam Pharmaceuticals to $320 from $350 and maintained its Outperform rating.
Oppenheimer lowered its price target on Alnylam Pharmaceuticals to $320 from $350 and maintained its Outperform rating.